Jw Holdings Cash Flow Conversion Efficiency
Jw Holdings cash flow conversion efficiency. Based on the latest financial reports, Jw Holdings (096760) has a cash flow conversion efficiency ratio of 0.118x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩66.90 Billion ≈ $45.34 Million USD) by net assets (₩567.12 Billion ≈ $384.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jw Holdings (2007–2024)
Cash flow conversion efficiency of Jw Holdings from 2007 to 2024. This chart illustrates how Jw Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Jw Holdings share price for real-time trading data and today's change.
Jw Holdings Cash Flow Conversion Ratio Explained
Jw Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jw Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jw Holdings ranked by their cash flow conversion efficiency. Also see 096760 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IMC S.A.
F:IM4
|
0.194x |
|
HIL Limited
NSE:HIL
|
0.049x |
|
Wismilak Inti Makmur Tbk
JK:WIIM
|
0.040x |
|
Willy Food
TA:WLFD
|
0.028x |
|
SPACSphere Acquisition Corp. Class A Ordinary Shares
NASDAQ:SSAC
|
0.000x |
|
GoldQuest Mining Corp.
V:GQC
|
-0.067x |
|
GD Express Carrier Bhd
KLSE:0078
|
0.009x |
|
Nucleus Software Exports Limited
NSE:NUCLEUS
|
0.137x |
Annual Cash Flow Conversion Efficiency for Jw Holdings (2007–2024)
The table below shows the annual cash flow conversion efficiency of Jw Holdings from 2007 to 2024. Review cash generation quality of Jw Holdings to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩521.39 Billion ≈ $353.34 Million |
₩97.89 Billion ≈ $66.34 Million |
0.188x | -41.70% |
| 2023-12-31 | ₩348.75 Billion ≈ $236.35 Million |
₩112.32 Billion ≈ $76.12 Million |
0.322x | +2.78% |
| 2022-12-31 | ₩333.26 Billion ≈ $225.85 Million |
₩104.43 Billion ≈ $70.77 Million |
0.313x | -12.89% |
| 2021-12-31 | ₩304.82 Billion ≈ $206.57 Million |
₩109.64 Billion ≈ $74.30 Million |
0.360x | +10.92% |
| 2020-12-31 | ₩334.97 Billion ≈ $227.00 Million |
₩108.62 Billion ≈ $73.61 Million |
0.324x | +15.54% |
| 2019-12-31 | ₩351.62 Billion ≈ $238.29 Million |
₩98.68 Billion ≈ $66.88 Million |
0.281x | -42.51% |
| 2018-12-31 | ₩401.00 Billion ≈ $271.75 Million |
₩195.76 Billion ≈ $132.67 Million |
0.488x | +1640.33% |
| 2017-12-31 | ₩374.73 Billion ≈ $253.95 Million |
₩10.51 Billion ≈ $7.12 Million |
0.028x | +126.65% |
| 2016-12-31 | ₩277.59 Billion ≈ $188.12 Million |
₩-29.21 Billion ≈ $-19.80 Million |
-0.105x | -18.65% |
| 2015-12-31 | ₩270.31 Billion ≈ $183.18 Million |
₩-23.98 Billion ≈ $-16.25 Million |
-0.089x | -9.45% |
| 2014-12-31 | ₩211.94 Billion ≈ $143.63 Million |
₩-17.18 Billion ≈ $-11.64 Million |
-0.081x | +64.60% |
| 2013-12-31 | ₩236.03 Billion ≈ $159.95 Million |
₩-54.03 Billion ≈ $-36.62 Million |
-0.229x | -5557.31% |
| 2012-12-31 | ₩205.46 Billion ≈ $139.24 Million |
₩861.85 Million ≈ $584.07K |
0.004x | -89.87% |
| 2010-12-31 | ₩192.45 Billion ≈ $130.42 Million |
₩7.97 Billion ≈ $5.40 Million |
0.041x | +6.94% |
| 2008-12-31 | ₩213.99 Billion ≈ $145.02 Million |
₩8.28 Billion ≈ $5.61 Million |
0.039x | -48.81% |
| 2007-12-31 | ₩214.73 Billion ≈ $145.52 Million |
₩16.24 Billion ≈ $11.01 Million |
0.076x | -- |
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair … Read more